Small Cap Feast

2nd November 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: 
No joiners today.

Leavers: 
No leavers today.





What’s Cooking In The IPO Kitchen?

Tekcapital announced intention to spin off and IPO on 2 October: MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. AIM Admission delayed, expected mid-November.

Stranger Holdings announced 02 October 2023, a Company formed for the purpose of acquiring a business, project or assets announces a Proposed Acquisition of up to a 70% interest in the Henkries Uranium Deposit and Prospecting Right in the Republic of South Africa. The Company will acquire this indirect ownership via the acquisition of two intermediary holding companies, namely Mayflower Energy Metals Limited and Neo Uranium Africa Proprietary Limited. The Acquisition constitutes a Reverse Takeover under the Listing Rules since, in substance it results in a fundamental change in the business of the issuer. Trading in the Existing Ordinary Shares continues to be suspended. It is anticipated that Re-Admission and trading in the Company's Enlarged Share Capital will occur on or around 7 November 2023.


Breakfast Buffet

Active Energy Group 4.35p £7.0m (AEG.L)
A producer of sustainably-sourced, energy-dense clean carbon products and technologies announces the appointment of Kate Nga Nguyen as the Company's Managing Director of Southeast Asia. Kate will focus on the deployment and expansion of Active Energy's activities throughout Southeast Asia, including building commercial partnerships and establishing manufacturing centres in the region. As part of this strategy, the Company plans to open an office in Vietnam in 2024.

Clean Power Hydrogen 15.25p £40.9m (CPH2.L)
The UK-based green hydrogen technology and manufacturing Group that has developed the Membrane-Free Electrolyser (MFE) announces that it has run the entire MFE110 system, successfully producing separated hydrogen and oxygen gases at its expected capacity, witnessed by a third party customer. Final tests will commence following the re-evaluation and control rectification, and upon successful completion, the MFE110 will be shipped to Northern Ireland Water's site where it will undergo site validation, integration and commissioning before beginning commercial production of hydrogen and medical grade oxygen.

e-therapeutics 9.59p £56.0m (ETX.L)
A Company integrating computational power and biological data to discover life-transforming RNAi medicines announces a strategic collaboration with Arcturis Data Limited, a UK data company with a real-world data platform to integrate the integrate Arcturis' Real-World Evidence (RWE). RWE outputs will be analysed by e-therapeutics using HepNet, its artificial intelligence AI-driven algorithms. Under the terms of the agreement, e-therapeutics will have exclusive rights to nominate novel gene targets derived from the collaboration to prosecute genetic medicines using its GalOmic RNAi platform.

Ethernity Networks 4.35p £6.5m (ENET.L)
The supplier of data processing semiconductor technology for networking appliances announces that it has signed an extended license contract for $475k (Contract) with a Tier 1 US based military aerospace customer. This Contract is further to an advanced payment received in October 2023 of $80k from the Customer. Payments for the Contract are expected to be received during November and December 2023. As a result, the total anticipated revenue from the Customer during Q4 2023 is $555k. The revenue associated with this Contract, together with ongoing business, are expected to represent the main revenue contributors for the Company during Q4 2023.

Inspiration Healthcare Group 39p £26.6m (IHC.L)
The medical technology Company focusing on neonatal intensive care medical devices announces the launch of the SLE1500, a compact respiratory support system that provides non-invasive ventilation modes to meet the needs of the smallest and most vulnerable neonatal patients requiring respiratory support. The Company’s initial launch is focused on the UK and Australia regions, with other market introductions due to follow.

Sabien Technology Group 6.75p £1.5m (SNT.L)
The Company focused on a Green Aggregation Strategy announces the publication of the audited annual report and accounts for the year to 30 June 2023. Revenue for the year increased 62% to £1.10m (2022: £0.68m), as a result gross profit increased to £704k (2022: £448k). The operating loss reduced to £627k (2022: loss £888k) and the Company announced total loss after tax of £0.7m. The Company holds cash less current borrowings at 30 September 2023 of £0.31m (2022: £0.63m). Sabien's Green Aggregation Strategy has focussed primarily on two principal technology led initiatives. M2G, the existing Sabien CO2 mitigation device for commercial boilers, and the City Oil Field Inc. (COF) plastic to oil technology.

Shanta Gold 10.8p £113.6m (SHG.L)
The East Africa-focused gold producer, developer and explorer provides an exploration update for the West Kenya Project in Kenya. The 2023 drilling programmes re-commenced in May 2023 with the primary aim of converting Inferred Resources to Indicated Resources at the Isulu-Bushiangala and Ramula deposits. This update follows on from the news announced last year at West Kenya, where the Company upgraded resources at Isulu and Bushiangala to 1.29 Moz grading 10.60 g/t Au, of which 721,900 ounces grading 11.45 g/t Au was upgraded to the Indicated category. Meanwhile at Ramula, upgraded resources of 469,800 ounces (oz) grading 2.41 g/t Au, including 416,700 ounces grading 2.43 g/t were found.

Southern Energy Corp 15p £20.1m (SOUC.L)
A U.S.-focused, growth-oriented natural gas producer announces the results of the conditional Fundraising announced on 1 November 2023. New Common Shares have been conditionally placed at a price of 15.5 pence per new Common Share, raising gross proceeds of US$5.0m (£4.1m). The Placing Price represents a 16.2 per cent. discount to the closing price on 1 November 2023. The net proceeds from the Fundraising will be to fund the completion of up to four drilled and uncompleted (DUC) wells at a cost of approximately US$3m per well.

Verici Dx 6.75p £11.5m (VRCI.L)
A developer of advanced clinical diagnostics for organ transplant announces that it will present a poster on the successful international clinical validation study for Clarava, the Company's pre-transplant blood-based prognostic test for the risk of early acute kidney transplant rejection, at the American Society of Nephrology's annual conference, ASN Kidney Week, being held from 2-5 November 2023 in Philadelphia, PA. Clarava is the only pre-transplant test currently available that can risk stratify patients based on their likely immune response to a transplanted organ.

Zoo Digital Group 43.75p £42.8m (ZOO.L)
The provider of end-to-end cloud-based localisation and media services to the global entertainment industry announces the expansion of its operations in India with the launch of its new production facility in Chennai. The launch of a second multi-purpose facility in India, alongside Mumbai, is a strategic move to support the production of dubbing and other media localisation services in regional languages. This second facility will scale up capacity to more than double ZOO India's revenues in FY24, while catering to the region's wide array of languages and the diverse post-production needs of our clients.

2 November 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram